Abstract

Peripheral neuropathy (PN) is a severe condition with numerous comorbidities. Approximately 4% of adults and the elderly develop polyneuropathy of various etiologies. The incidence of PN likely increases with age and multiple facets of declining health. Many pharmacological agents are inadequate in treating PN, and some have significant side effects. Thus, other treatment options, methods, and modalities to treat PN should be advanced and explored. This retrospective study reports a comparison of the clinical effectiveness of specific neurostimulation and photomodulation (low-level laser therapy) modalities with therapeutic nutrition in the treatment of the symptoms of PN. Most participants reported some level of symptom relief with each of the treatment components, while neurostimulation provided nearly universal relief of all PN symptoms in the participants surveyed.

Keywords: Low-Level Laser; Neurostimulation; Peripheral Neuropathy; Photobiomodulation; Therapeutic Nutrition

References

1. Griebeler ML., et al. “Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis”. Annals of Internal Medicine 9 (2014): 639-649. https://www.ncbi.nlm.nih.gov/pubmed/25364885
2. Klein SE., et al. “Evaluation of peripheral neuropathy of unknown origin in an outpatient foot and ankle practice”. Foot and Ankle International 9 (2015): 1058-1063. https://www.ncbi.nlm.nih.gov/pubmed/25967255
3. Hanewinckel R., et al. “Prevalence of polyneuropathy in the general middle-aged and elderly population”. Neurology18 (2016): 1892-1898. https://www.ncbi.nlm.nih.gov/pubmed/27683845
4. Suzuki M. “Peripheral neuropathy in the elderly”. The Handbook of Clinical Neurology 115 (2013): 803-813. https://www.ncbi.nlm.nih.gov/pubmed/23931816
5. Griebeler ML., et al. “Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis”. Annals of Internal Medicine 9 (2014): 639-649. https://www.ncbi.nlm.nih.gov/pubmed/25364885
6. Rudroju N., et al. “Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis”. Pain Physician6 (2013): E705-E714. https://www.ncbi.nlm.nih.gov/pubmed/24284851
7. Alabdali M., et al. “Choosing drugs for the treatment of diabetic neuropathy”. Expert Opinion on Pharmacotherapy 12 (2015): 1805-1814. https://www.ncbi.nlm.nih.gov/pubmed/26161591
8. Kuo KL., et al. “Single-versus multiple-drug pharmacotherapy in the management of diabetic painful neuropathy”. Journal of Pain and Palliative Care Pharmacotherapy 3 (2016): 184-194. https://www.ncbi.nlm.nih.gov/pubmed/27541383
9. Hanewinckel R., et al. “Peripheral neuropathies”. The Handbook of Clinical Neurology 138 (2016): 263-282. https://www.ncbi.nlm.nih.gov/pubmed/27637963
10. Singh R., et al. “Diabetic peripheral neuropathy: current perspective and future directions”. Pharmacological Research 80 (2014): 21-35. https://www.ncbi.nlm.nih.gov/pubmed/24373831
11. Callaghan B and Feldman E. “The metabolic syndrome and neuropathy: therapeutic challenges and opportunities”. Annals of Neurology 3 (2013): 397-403. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881591/
12. Lei Q., et al. “Statins in nervous system-associated diseases: angels or devils?” Pharmazie6 (2014): 448-454. https://www.ncbi.nlm.nih.gov/pubmed/24974580
13. Hershman DL., et al. “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline”. Journal of Clinical Oncology 18 (2014): 1941-1967. https://www.ncbi.nlm.nih.gov/pubmed/24733808
14. Cohen JS. “Peripheral neuropathy associated with fluoroquinolones”. Annals of Pharmacotherapy 12 (2001): 1540-1547. https://www.ncbi.nlm.nih.gov/pubmed/11793615
15. Hedenmalm K and Spigset O. “Peripheral sensory disturbances related to treatment with fluoroquinolones”. Journal of Antimicrobial Chemotherapy 4 (1996): 831-837. https://www.ncbi.nlm.nih.gov/pubmed/8722551
16. Singh J., et al. “Acute onset sensory polyneuropathy due to metronidazole therapy”. The Journal of the Association of Physicians of India 9 (2015): 87-88. https://www.ncbi.nlm.nih.gov/pubmed/27608880
17. Park KI., et al. “Metronidazole neurotoxicity: sequential neuroaxis involvement”. Neurology India 1 (2011): 104-107. https://www.ncbi.nlm.nih.gov/pubmed/21339674
18. Wang CZ., et al. “Low-level laser irradiation improves functional recovery and nerve regeneration in sciatic nerve crush rat injury model”. PLoS One8 (2014): e103348. https://www.ncbi.nlm.nih.gov/pubmed/25119457
19. Abdel-Wahhab KG., et al. “Efficiencies of low-level laser therapy (LLLT) and gabapentin in the management of peripheral neuropathy: diabetic neuropathy”. Biotechnology and Applied Biochemistry 1 (2018): 161-173. https://www.ncbi.nlm.nih.gov/pubmed/29527628
20. Bunner AE., et al. “A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study”. Diabetes Nutrition 5 (2015): e158. https://www.ncbi.nlm.nih.gov/pubmed/26011582
21. Farvid MS., et al. “Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation”. Diabetes Research and Clinical Practice 1 (2011): 86-94. https://www.ncbi.nlm.nih.gov/pubmed/21496936
22. Wager TD., et al. “An fMRIbased neurologic signature of physical pain”. The New England Journal of Medicine 15 (2013): 1388-1397. https://www.nejm.org/doi/full/10.1056/NEJMoa1204471
23. Thakral G., et al. “Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy”. Journal of Diabetes Science and Technology 5 (2013):1202-1209. https://www.ncbi.nlm.nih.gov/pubmed/24124947
24. Mekhail NA., et al. “Clinical applications of neurostimulation: forty years later”. Pain Practice 2 (2010): 103-112. https://europepmc.org/article/med/20070547